Drug Database
SA

saxagliptin (Bessin)

✓ Approved

Sino Biopharmaceutical Co., Ltd · DPP4 · Small Molecule

What is saxagliptin?

saxagliptin is a small molecule developed by Sino Biopharmaceutical Co., Ltd. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesBessin
CompanySino Biopharmaceutical Co., Ltd
Drug ClassSmall Molecule
Molecular TargetDPP4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Sino Biopharmaceutical Co., Ltd

Mechanism of Action

Molecular Targets

saxagliptin acts on 1 molecular target:

DPP4dipeptidyl peptidase 4 (CD26, DPPIV)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

saxagliptin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

Related Research Articles

PubMedHealthcare quarterly (Toronto, Ont.)2026-08-30

Addressing Canada's Pharmaceutical Research and Development Intensity Gap: The Role of Health Data Transformation.

Mullie Thomas T, Chuck Anderson A

The life sciences industry, and specifically the pharmaceutical sub-sector, is a major funder of private sector research and development. Canada's life sciences industry reinvests less of its revenues in research and development (R&D) activities than those in peer countries, which hinders innovation, creates supply risks and contributes to Canada's poor productivity growth. Traditional approaches to incentivizing reinvestment, including tax incentives, direct funding and public research spending, have failed. As an alternative, transforming Canada's health data systems would enable faster and more comprehensive secondary use, making R&D investments safer and more productive. Our peers are already pursuing this strategy, meaning Canada risks being left behind unless we act.

PMID 42669639
Read full article →
PubMedExploratory research in clinical and social pharmacy2026-08-30

In defence of the drug, two hearts, one profession: Reintegrating medicines expertise and patient-centred care in pharmacy's professional identity.

Davies Neal M NM

For more than three decades, pharmacy has narrated its evolution as a movement away from the product and toward the patient. The pharmaceutical care era ushered in by Hepler and Strand in 1990 framed dispensing and product expertise as a chrysalis the profession needed to shed in order to mature. That framing has been useful, but it has also been misread, and the misreading has now been institutionalised. Some accreditation councils, regulatory and licensing bodies, and advocacy bodies have positioned the profession as one moving away from a so-called "product centric" past. The thesis of this commentary is otherwise. Pharmacy has never had a single heart; it has always had two, one beating for the drug and the other for the patient, and they have always beaten in the same chest, for four centuries and more. The pharmacist's claim to a place at the patient's bedside rests entirely on what the pharmacist knows about the molecule: medicinal chemistry, pharmaceutics, compounding, biopharmaceutics, pharmacokinetics, pharmacogenomics, radiopharmacy, pharmacognosy and now pharmaceutical artificial intelligence. The argument here is not nostalgic but expansive. Embrace them all. Without the drug, the diagnosis is a verdict, not a treatment; and without the pharmacist, no drug appears.

PMID 42668522
Read full article →
PubMedDrug delivery and translational research2026-08-30

Biodegradable furylacryloyl-modified hyaluronan: in vivo evaluation and its use as a nanofibrous drug delivery system.

Brtková Barbora B, Bártová Tereza T, Piskláková Lenka L, Šimek Matěj M et al.

Furylacryloyl-modified hyaluronan (F-HA) has emerged as an appropriate material for the fabrication of UV-crosslinkable, water-stable nanofibrous scaffolds with preserved porosity. However, the safety profile and in vivo applicability of F-HA have not yet been established. In this study, we present biological assessment of F-HA, including biodegradation studies and its first in vivo evaluation in C57BL/6J mice following both intravenous and intraperitoneal administration. The results demonstrate good tolerability under the tested conditions and confirm biodegradability. Additionally, we confirm the ability of composite nanofibers consisting of F-HA with established nanofiber-forming polymers, to incorporate active pharmaceutical ingredients (API), while retaining their porous structure and favorable mechanical properties. Importantly, the incorporation of F-HA alters the release profile of embedded API. Using octenidine dihydrochloride (OCT) as a model compound, we demonstrate sustained release from F-HA/lauroyl hyaluronan (L-HA) nanofibrous scaffolds in biologically relevant protein-containing media, while retaining its structural integrity, thus supporting its suitability for biomedical applications. These findings highlight the potential of F-HA as a versatile platform for the development of advanced nanofibrous biomaterials with translational relevance in topical wound healing and drug delivery.

PMID 42668347
Read full article →
PubMedmAbs2026-08-30

Quantifying molecular specificity in excipient-driven antibody solubilization.

Han Zexiang Z, Erkamp Nadia A NA, Scrutton Rob R, Licari Giuseppe G et al.

Excipients are widely used to suppress the self-association of therapeutic proteins, yet their mechanisms of action are not well understood and often assumed to be nonspecific. Here we show that excipient-mediated solubilization of therapeutic antibodies is markedly molecularly specific. Using a high-throughput combinatorial droplet microfluidic platform, we systematically quantify the effects of common pharmaceutical excipients across a diverse panel of monoclonal antibodies (mAbs). Although all studied excipients enhance solubility, their effects can vary significantly between antibodies, spanning dynamic ranges from approximately 7-fold to over 200-fold. Integrating experimental solubilization measurements with sequence- and structure-derived molecular descriptors, we identify interpretable physicochemical determinants underlying excipient responses; for example, the histidine effect is strongly dependent on mAb dipole moment. Our findings reveal trends that highlight the molecular specificity and complexity of antibody-excipient interactions, as well as the limitations of purely generic formulation rules. Overall, this study provides a quantitative framework for analyzing excipient effects across diverse antibodies and supports the development of predictive approaches for rational formulation design. The integration of high-throughput experimentation with molecular feature analysis offers a foundation for improving our understanding and prediction of antibody-specific formulation behavior.

PMID 42668421
Read full article →
PubMedToxicology reports2026-08-30

Cardiotoxicological assessment of crocin-coated silver nanoparticles in an experimental rat model.

Ziaaldini Mohammad Amin Abdolahi MAA, Fakhrtaha Tahora T, Samarghandian Saeed S, Farkhondeh Tahereh T

Silver nanoparticles (AgNPs) are widely used for various industrial and biomedical applications; however, their potential cardiotoxicity remains insufficiently understood and requires further investigation. We evaluated the cardiotoxic effects of AgNPs and crocin-coated AgNPs (CR-AgNPs) administered at doses of 20, 40, and 80 µg/kg in male Wistar rats. Forty-two rats were randomly allocated to seven groups as follows: The groups included a control group (normal saline), three AgNPs-treated groups (20, 40, and 80 µg/kg), and three crocin-coated AgNPs-treated groups (20, 40, and 80 µg/kg), all of which received treatment via oral gavage for 30 days. At the end of the experiment, the animals were anesthetized with ketamine and xylazine, and blood samples and cardiac tissues were collected for biochemical and histopathological analyses. Our findings showed that malondialdehyde (MDA) levels were significantly increased in the AgNPs 80 group compared with the control group. In addition, administration of CR-AgNPs at 80 µg/kg significantly reduced MDA levels compared with the AgNPs 80 group. Histopathological examination confirmed the toxic effect of AgNPs at 80 µg/kg, as evidenced by mild interstitial edema and localized separation of myocardial muscle fibers. In conclusion, these findings suggest that CR-AgNPs may represent a safer alternative for pharmaceutical applications by reducing the risk of subacute cardiotoxicity in experimental animals. Further investigations are required to provide additional evidence in this field.

PMID 42668648
Read full article →
PubMedPhytomedicine : international journal of phytotherapy and phytopharmacology2026-08-30

Ligustilide and tectoridin from Danggui Buxue Decoction synergistically attenuate atherosclerosis by targeting the CD36/TRPM2 axis and TNF-α/NF-κB pathway.

Li Xin X, Zheng Shu S, Song Yuqiong Y, Chen Xue X et al.

Atherosclerosis (AS) is a common chronic disease and the primary pathological basis for myocardial infarction, stroke, and other disabling conditions. Danggui Buxue Decoction (DBD) is a classic formula in Traditional Chinese Medicine (TCM) normally used for deficiency patterns. However, whether DBD can alleviate atherosclerosis, which bioactive constituents are responsible, and which molecular mechanisms are involved remain to be further investigated. This study aims to characterize the absorbed bioactive components of DBD and decipher the multi-target mechanisms by which it counteracts atherosclerosis, providing a scientific rationale for its clinical application. This study employs an integrated approach combining network pharmacology, WGCNA, and machine learning screening strategies, supported by experimental validation, to systematically elucidate the active pharmaceutical ingredients and molecular mechanisms of anti-AS effects of serum-absorbed constituents of DBD after oral administration. Network pharmacology and machine learning analyses predicted CD36, TRPM2, and TNF-α as three core targets for DBD intervention in AS. CETSA and BLI experiments further confirmed stable binding of Ligustilide and Tectoridin in DBD to these targets. In vivo and in vitro experiments demonstrated that the combined treatment of Ligustilide and Tectoridin effectively inhibit macrophage foaming, mitigate oxidative damage, and downregulate inflammatory cytokine release. This study successfully identified Ligustilide and Tectoridin as the primary bioactive constituents of DBD against atherosclerosis. By modulating CD36, TRPM2, and TNF-α, these compounds synergistically inhibit foam cell formation and inflammation, offering a novel pharmacological perspective on the anti-AS efficacy of DBD.

PMID 42669225
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about saxagliptin